Inmaculada MORENO (Spain)
She was graduated in Biochemical Sciences in 2002 and obtained her European PhD in 2007 in Molecular microbiology, which was awarded the best PhD thesis. During her postdoctoral training she specialized on Molecular Oncology and then in Regenerative Medicine. From 2014 is a researcher at the R&D department of Igenomix where she is currently the research manager. From 2015 she collaborates at the Reproductive and Stem Cell Biology lab at Stanford University School of Medicine, where she is a Visiting Scholar from 2016. She is the author of more than 20 international publications in peer-review journals and has participated in several international projects.
During reproductive life, the human endometrium undergoes around 500 cycles of growth, breakdown and regeneration. This outstanding regenerative capability is the basis for cyclic endometrial preparation and its dysfunction is involved in pathological disorders. Asherman’s syndrome (AS) is characterized by the presence of intrauterine adhesions and endometrial atrophy (EA) prevents the endometrium from growing thicker than 5 mm, resulting in menstruation disorders and infertility. A prospective, experimental, non-controlled study with 18 patients with refractory AS or EA has shown that cell therapy using autologous peripheral blood CD133+ bone marrow-derived stem cells (BMDSCs) offer a safe and efficient therapeutic approach for these patients. This novel autologous cell therapy is a promising therapeutic option for patients with these incurable pathologies and a wish to conceive.